Raising the Bar in HR+/HER2- Early Breast Cancer: CDK4 and 6 Inhibitors

preview_player
Показать описание
  1. PeerView Oncology
  2. Dr. Joyce O’Shaughnessy
  3. Dr. Judy Boughey
  4. Professor Stephen Johnston
  5. CME
  6. meded
Рекомендации по теме
Raising the Bar 1:09:24

Raising the Bar in HR+/HER2- Early Breast Cancer: CDK4 and 6 Inhibitors

Raising the Bar 0:32:54

Raising the Bar in HER2-Positive Breast Cancer

Management of HR-Positive/HER2-Negative 0:34:58

Management of HR-Positive/HER2-Negative Early Breast Cancer: Taking Direction From the Updated Gu...

Expert Report on 0:06:39

Expert Report on advances in the management of HER2-negative and HER2-low advanced breast cancer

Changing Treatment Landscape 2:17:54

Changing Treatment Landscape In HR+HER2 aBC

Dr. McCann on 0:01:47

Dr. McCann on Prognosis for Patients With HER2-Positive Breast Cancer

Breaking Down Barriers 0:55:30

Breaking Down Barriers to Treatment Adherence and Persistence in HR+/HER2- Early Breast Cancer

Is it time 0:01:15

Is it time to reconsider the locoregional approach in HER2+ breast cancer?

Update of EMERALD 0:00:46

Update of EMERALD by duration of CDK4/6i in metastatic setting: elacestrant v SoC in ER+/HER2- mBC

TIBCS Spotlight EP14 0:01:37

TIBCS Spotlight EP14 – Encounter Dr. Nadia Harbeck & Dr. Yin-Yin Chen

New Advances and 0:29:21

New Advances and Opportunities for Improvement in HR+/HER2- Early Breast Cancer

Integrating Antibody-Drug Conjugates 0:54:18

Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metas...

Drs. O’Shaughnessy, Boughey, 1:08:22

Drs. O’Shaughnessy, Boughey, & Johnston discuss Early HR+ Breast Cancer: https://bit.ly/3BIHC4u...

New Perspectives on 0:59:44

New Perspectives on the Full Spectrum of HER2 Expression in Breast Cancer

What’s new with 0:04:10

What’s new with HER2-neu inhibition

ASCO 2022: Practice 0:03:48

ASCO 2022: Practice changing data in breast cancer: DESTINYBreast04 - her2low English, Prof. Harbeck

Palbociclib shows improved 0:06:38

Palbociclib shows improved PFS but not improved OS for ER+ HER2- mBC patients

Dr. Hurvitz on 0:01:03

Dr. Hurvitz on Steps to Take With HER2-Positive Breast Cancer Research

TROPiCS-02 shows sacituzumab 0:04:42

TROPiCS-02 shows sacituzumab govitecan OS benefit in HR+, HER2– advanced breast cancer | Hope Rugo

Expanding Treatment Options 1:02:48

Expanding Treatment Options in ER+/HER2- Breast Cancer: SERDs, SERMs, SERCAs, and More

Metastatic Breast Cancer: 0:44:23

Metastatic Breast Cancer: Leveraging Clinical Pathways to Navigate a Complex Treatment Landscape:

Adjuvant CDK4 and 0:58:22

Adjuvant CDK4 and 6 Inhibition to Prevent Recurrences in High-Risk HR+/HER2- Early Breast Cancer

2022 West Oncology 0:23:51

2022 West Oncology Conference | Precision Oncology in HR+ Breast Cancer

Educational Sessions: 'CDK4/6 0:21:35

Educational Sessions: 'CDK4/6 for ER+'